Literature DB >> 17261875

The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis.

Masako Tabuchi1, Katsumi Inoue, Hitomi Usui-Kataoka, Kazuko Kobayashi, Misako Teramoto, Koji Takasugi, Kenichi Shikata, Masahiro Yamamura, Kenji Ando, Keiichiro Nishida, Junko Kasahara, Noriaki Kume, Luis R Lopez, Kazuaki Mitsudo, Masakiyo Nobuyoshi, Tatsuji Yasuda, Toru Kita, Hirofumi Makino, Eiji Matsuura.   

Abstract

C-reactive protein (CRP) is one of the strongest independent predictors of cardiovascular disease. We have previously reported that oxidized LDL (oxLDL) interacts with beta2-glycoprotein I (beta2GPI), implicating oxLDL/beta2GPI complexes as putative autoantigens in autoimmune-mediated atherosclerotic vascular disease. In this study, we investigated the interaction of CRP with oxLDL/beta2GPI complexes and its association with atherosclerosis in patients with diabetes mellitus (DM). CRP/oxLDL/beta2GPI complexes were predominantly found in sera of DM patients with atherosclerosis. In contrast, noncomplexed CRP isoforms were present in sera of patients with acute/chronic inflammation, i.e., various pyrogenic diseases, rheumatoid arthritis (RA), and DM. Immunohistochemistry staining colocalized CRP and beta2GPI together with oxLDL in carotid artery plaques but not in synovial tissue from RA patients, strongly suggesting that complex formation occurs during the development of atherosclerosis. Serum levels of CRP correlated with soluble forms of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, and oxLDL/beta2GPI complexes correlated with total cholesterol and hemoglobin A1c. Thus, the generation of CRP/oxLDL/beta2GPI complexes seems to be associated with arterial inflammation, hyperglycemia, and hypercholesterolemia. CRP/oxLDL/beta2GPI complexes can be distinguished from pyrogenic noncomplexed CRP isoforms and may represent a more specific and predictive marker for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261875     DOI: 10.1194/jlr.M600414-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

Review 1.  Redox-reactive autoantibodies: biochemistry, characterization, and specificities.

Authors:  John A McIntyre; W Page Faulk
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 2.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

3.  The combination of CRP isoforms with oxLDL decreases TNF-α and IL-6 release by U937-derived macrophages.

Authors:  Imtissal Krayem; Samer Bazzi; Marc Karam
Journal:  Biomed Rep       Date:  2017-07-21

4.  Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin.

Authors:  Shirya Rashid
Journal:  World J Cardiol       Date:  2009-12-31

5.  8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study.

Authors:  Savino Sciascia; Dario Roccatello; Maria Tiziana Bertero; Debora Di Simone; Domenico Cosseddu; Antonella Vaccarino; Mario Bazzan; Daniela Rossi; Cesar Garcia-Fernandez; Leticia Ceberio; Stefania Stella; Elisa Menegatti; Simone Baldovino
Journal:  Inflamm Res       Date:  2012-05-26       Impact factor: 4.575

Review 6.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

7.  In vitro effects of azide-containing human CRP isoforms and oxLDL on U937-derived macrophage production of atherosclerosis-related cytokines.

Authors:  Dania Jundi; Imtissal Krayem; Samer Bazzi; Marc Karam
Journal:  Exp Ther Med       Date:  2020-09-04       Impact factor: 2.447

Review 8.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

9.  Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome.

Authors:  Omer Yiginer; Fatih Ozcelik; Tugrul Inanc; Mustafa Aparci; Namik Ozmen; Bekir Yilmaz Cingozbay; Ejder Kardesoglu; Selami Suleymanoglu; Goksel Sener; Bekir Sitki Cebeci
Journal:  Clin Res Cardiol       Date:  2007-12-28       Impact factor: 5.460

Review 10.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Saurabh S Dhawan; Arshed A Quyyumi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.